In the PACIFIC trial, durvalumab following chemoradiotherapy significantly improved survival in patients with unresectable ...
A new AI model called COMPASS uses tumor gene expression data to predict which patients will respond to cancer immunotherapy ...
Immune checkpoint inhibitor colitis is a common immune-related adverse event associated with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management ...
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patie ...
Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they ...
A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients.
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an ...
A real-world analysis investigates the impact of concurrent GLP-1 RA use on long-term survival and the safety profile of patients with solid and hematologic malignancies receiving immune checkpoint ...
Morning Overview on MSN
An FDA-approved drug added five months of survival in tough breast cancer
Patients diagnosed with metastatic triple-negative breast cancer, one of the most aggressive and treatment-resistant forms of ...
The domestic patent for Keytruda, the world’s top-selling medicine by annual sales, is scheduled to expire in 2028. A fierce ...
AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...
Immune checkpoint inhibitors like anti-PD-1 have transformed melanoma treatment, yet more than half of patients fail to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results